Skip to main content
Log in

Plasma tenoxicam concentrations after single and multiple oral doses

  • Original Papers
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The pharmacokinetics of single- and multiple-dose administration of tenoxicam 20 mg were evaluated in 8 healthy males. Maximum plasma concentration (Cmax) after the first dose was 2.76±0.48 μg/ml (mean±s.d.) and the time to reach Cmax (Tmax) was 5.0±3.0 h. The area under the plasma concentration-time curve (AUCo-∼) after a single administration of tenoxicam was 242.5±73.5 μg x h/ml. The elimination half-life (t 1/2 ) was 66.3±15.8 h and the plasma concentration at 24 hours after dosing (Cmin) was 1.84±0.33 μg/ml. Steady-state plasma concentrations of tenoxicam were virtually reached after 10 consecutive daily doses. At steady-state, Cmax averaged 13.63±3.33 μg/ml and Tmax remained 5.0±3.0 hours. AUC within a dosing interval at steady-state was 262.2±67.0 μg x h/ml, Cminss was 9.67±3.25 μg/ml, and t 1/2 averaged 74.2±13.3 h. The average fluctuation during multiple-dose administration was 26.8±8.0% and the accumulation ratio was 5.82±0.60. Steady-state pharmacokinetic parameters predicted from the first-dose data slightly underestimated observed values, but the results supported the assumption of linear pharmacokinetics during multiple-dose tenoxicam administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dell D., Joly R., Meister W., Arnold W., Partos C, Guldimann B. (1984): Determination of tenoxicam and the isolation, identification and determination of Ro 17–6661, its major metabolite, in human urine. J. Chromatogr., 317, 483–492.

    Article  CAS  PubMed  Google Scholar 

  2. Crevoisier C, Heizmann P. (1986): Pharmacokinetics of tenoxicam. In: Roxborough S.M. ed., Tenoxicam: Presentations to the EULAR Symposium. Basel, EULAR. Litera Rheumatologica, 5, 7–15.

    Google Scholar 

  3. Heintz R, Guentert T.W. (1986): Pharmacokinetic profile of tenoxicam. In: Fermer H., Stoiber W. eds, Tenoxicam, a New Nonsteroidal Anti-inflammatory Drug. Basel, EULAR. Litera Rheumatologica, 6, 23–34.

    Google Scholar 

  4. Heintz R.C., Guentert T.W., Enrico J.F., Dubach U.C., Brandt R, Jeunet F.S. (1984): Pharmacokinetics of tenoxicam in healthy human volunteers. Eur. J. Rheumatol. Inflamm., 7, 33–44.

    CAS  PubMed  Google Scholar 

  5. Bird H A, Allen J.G, Dixon J.S., Wright V. (1985): A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. Eur. J. Rheumatol. Inflamm., 8, 47–52.

    CAS  PubMed  Google Scholar 

  6. Francis R.J., Dixon J.S., Lowe J.R., Harris P.A. (1985): The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. Eur. J. Drug Metab. Pharmacokinet., 10, 309–314.

    Article  CAS  PubMed  Google Scholar 

  7. Horber F.F., Guentert T.W., Weidekamm E., Heizmann P., Descoeudres C., Frey F.J. (1986): Pharmacokinetics of tenoxicam in patients with impaired renal function. Eur J. Clin. Pharmacol, 29, 697–701.

    Article  CAS  PubMed  Google Scholar 

  8. Bird H.A., Francis R.J., LeGallez P., Hill J., Dixon J.S., Allen J.G., Wright V. (1985): Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly. Eur. J. Rheumatol. Inflamm., 8, 60–69.

    CAS  PubMed  Google Scholar 

  9. Hamdy R.C., Mumane B., Perera N., Woocock K., Koch I.M. (1982): The pharmacokinetics of benoxaprofen in elderly subjects. Eur. J. Rheumatol. Inflamm., 5, 69–75.

    CAS  PubMed  Google Scholar 

  10. Kamal A., Koch I.M. (1982): Pharmacokinetic studies of benoxaprofen in geriatric patients. Eur. J. Rheumatol. Inflamm., 5, 76–81.

    CAS  PubMed  Google Scholar 

  11. Advenier C., Roux A., Gobert C., Massias P., Varoquaux O., Flouvat B. (1983): Pharmacokinetics of ketoprofen in the elderly. Br. J. Clin. Pharmacol., 16, 65–70.

    CAS  PubMed  Google Scholar 

  12. Ritch A.E.S., Perera W.N.R., Jones C.J. (1982): Pharmacokinetics of azapropazone in the elderly. Br. J. Clin. Pharmacol., 14, 116–119.

    CAS  PubMed  Google Scholar 

  13. Richardson C.I., Blocka K.L.N., Ross S.G., Verbeeck R.K. (1985): Effects of age and sex on piroxicam disposition. Clin. Pharmacol. Ther., 37, 13–18.

    CAS  PubMed  Google Scholar 

  14. Heizmann P., Kömer J., Zinapold K. (1986): Determination of tenoxicam in human plasma by high-performance liquid chromatography. J. Chromatogr., 374, 95–102.

    Article  CAS  PubMed  Google Scholar 

  15. Metzler C.M., Elfring G.L., Even A.J. (1974): A package of computer programs for pharmacokinetic modelling. Biometrics, 30, 562–563.

    Article  Google Scholar 

  16. Meystre A., Leishman B., Eckert M. (1982): NONLIN: A new version for simplified use in BASIC computer systems. Meth. Inf. Med., 21, 187–190.

    CAS  Google Scholar 

  17. Richardson C.J., Blocka K.L.N., Ross S.G., Verbeeck R.K. (1987): Piroxicam and 5′-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. Eur. J. Clin. Pharmacol, 32, 89–91.

    Article  CAS  PubMed  Google Scholar 

  18. Colburn W.A. (1983): Estimating the accumulation of drugs. J. Pharm. Sci.,72, 833–834.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crevoisier, C., Heizmann, P., Forgo, I. et al. Plasma tenoxicam concentrations after single and multiple oral doses. Eur. J. Drug Metab. Pharmacokinet. 14, 23–27 (1989). https://doi.org/10.1007/BF03190838

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190838

Key words

Navigation